Abstract: The invention relates to a method for amelioration of neurological outcome in humans with spinal cord damage by administration of ganglioside GM1. Another object of the present invention is to provide combination therapies for the treatment of spinal cord damage comprised of the administration of the ganglioside GM1 and other drugs which have therapeutical benefit in patients with spinal cord damage, preferably methylprednisolone.
Type:
Grant
Filed:
April 18, 2002
Date of Patent:
September 16, 2003
Assignee:
Fidia Farmaceutici S.p.A.
Inventors:
Gino Toffano, Alberta Leon, Marino Massarotti
Abstract: The present invention refers to pharmaceutical compositions containing monosialoganglioside GM1 or a derivative thereof, namely, the inner ester AGF2 and the methyl ester AGF4, suitable for the treatment of Parkinson's disease. A further object of the present invention is a therapy for Parkinson's disease based on the associated administration of the aforesaid compounds and, in addition, the N-dichloroacetyl lyso GM1 (LIGA 20) with known pharmaceuticals active in the aforesaid treatment, in particular with L-dopa and/or BDNF.
Type:
Grant
Filed:
September 12, 1994
Date of Patent:
September 16, 2003
Assignee:
Fidia S.p.A.
Inventors:
Gino Toffano, Aurelio Romeo, Stephen Drake Skaper
Abstract: The present invention relates to novel amidino compound of formula (I):
to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.
Type:
Grant
Filed:
August 15, 2001
Date of Patent:
September 16, 2003
Assignee:
SmithKline Beecham Corporation
Inventors:
Richard Mansfield Beams, Martin James Drysdale, Karl Witold Franzmann, Anthony Joseph Frend, Harold Francis Hodson, Richard Graham Knowles, Daryl David Rees, David Alan Sawyer
Abstract: The invention provides edible compositions such as solid particulate sweeteners, boiled sweets, chocolate and chewing gum, wherein the compositions comprise at least 10% on a dry weight basis of one or more substances having an endothermic heat of solution of at least −30 kJ/kg and at least 10% on a dry weight basis of a substantially amorphous solid trehalose. The one or more substances having an endothermic heat of solution may comprise dextrose monohydrate or a crystalline sugar alcohol. The invention also provides processes suitable for the production of such edible compositions, wherein the processes comprise the step of dry mixing amorphous trehalose particles in an amount of at least 10% based on the dry weight of the composition with one or more other edible ingredients to form a dry mixture.
Abstract: The present invention relates to oligosaccharides of formula:
to mixtures thereof, to diastereoisomers thereof, to a process for preparing them, to pharmaceutical compositions containing them, and to their use in preventing or treating a disease associated with an inflammatory process involving the production of nitric oxide.
Type:
Grant
Filed:
October 20, 2000
Date of Patent:
September 9, 2003
Assignee:
Aventis Pharma
Inventors:
Pierre Mourier, Elisabeth Perrin, Jean-marie Stutzmann, Christian Viskov, Florence Wahl
Abstract: Carboxyl-containing fructans such as carboxymethylinulin can be successfully used to prevent deposition of scale composed of, for example, calcium, barium and strontium salts of sulphuric acid and carbonic acid in oil extraction. In the oil extraction method, 0.5-200 ppm of a carboxyl-containing fructan that contains 0.3-3 carboxyl groups per mono-saccharide unit is incorporated in the process water, in the process equipment or in the oil-containing formation.
Abstract: The present invention relates to a purified, easily produced poly-&bgr;-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a &bgr;-1→4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.
Type:
Grant
Filed:
May 29, 2001
Date of Patent:
August 26, 2003
Assignee:
Marine Polymers Technologies
Inventors:
John N. Vournakis, Sergio Finkielsztein, Ernest R. Pariser, Mike Helton
Abstract: This invention relates to new cyclodextrin derivatives, processes for producing these cyclodextrin derivatives, and inclusion complexes comprised of the new cyclodextrin derivatives and guest molecules, as well as methods of making such materials and related materials and methods of using the same.
Type:
Grant
Filed:
January 11, 2002
Date of Patent:
August 26, 2003
Assignee:
Eastman Chemical Company
Inventors:
Charles M. Buchanan, Steven N. Falling, Juanelle L. Lambert, Shannon E. Large, Jozsef Szejtli, Lajos Szente, Laszlo Jicsinszky
Abstract: The invention relates to an improved process for the synthesis and application of sugar esters, that are useful as effective, environmentally-safe pesticides for the control of soft-bodied arthropod pests.
Type:
Grant
Filed:
July 11, 1994
Date of Patent:
August 19, 2003
Assignee:
The United States of America as represented by the Secretary
of Agriculture
Abstract: The invention relates to an improved process for the synthesis and application of sugar esters, that are useful as effective, environmentally-safe pesticides for the control of soft-bodied arthropod pests.
Type:
Grant
Filed:
April 7, 1997
Date of Patent:
August 12, 2003
Assignee:
The United States of America as represented by the Secretary
of Agriculture
Abstract: This invention relates to an improved catalyst, comprising a carbon support having a noble metal at its surface, for use in catalyzing liquid phase oxidation reactions, especially in an acidic oxidative environment and in the presence of solvents, reactants, intermediates, or products which solubilize noble metals; a process for the preparation of the improved catalyst; a liquid phase oxidation process using such a catalyst wherein the catalyst exhibits improved resistance to noble metal leaching, particularly in acidic oxidative environments and in the presence of solvents, reactants, intermediates, or products which solubilize noble metals; and a liquid phase oxidation process in which N-(phosphonomethyl)iminodiacetic acid (i.e., “PMIDA”) or a salt thereof is oxidized to form N-(phosphonomethyl)glycine (i.e., “glyphosate”) or a salt thereof using such a catalyst wherein the oxidation of the formaldehyde and formic acid by-products into carbon dioxide and water is increased.
Type:
Grant
Filed:
September 29, 1999
Date of Patent:
August 5, 2003
Assignee:
Monsanto Technology LLC
Inventors:
Jerry R. Ebner, Mark A. Leiber, Kam-To Wan, Peter E. Rogers, Jingyue Liu, Anthony Woods
Abstract: A photocurable hyaluronic acid derivative of the present invention comprises hyaluronic acid and a photoreactive crosslinking group bonded thereto, wherein a 1.0 wt. % aqueous solution of the photocurable hyaluronic acid derivative obtained by dissolving the solid photocurable hyaluronic acid derivative in an aqueous solvent, is capable of passing through a porous filter having a pore size of 0.45 &mgr;m and a diameter of 25 mm at a rate of not less than 2 ml/minute at 24° C. under a pressure of 5.0 Kg/cm2; and a process for producing the photocurable hyaluronic acid derivative; and a photocured crosslinked-hyaluronic acid derivative; a medical material using the photoreactive hyaluronic acid derivative and a medical material using the photocured crosslinked-hyaluronic acid derivative.
Abstract: The present invention relates to a purified, easily produced poly-&bgr;-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a &bgr;-1→4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.
Type:
Grant
Filed:
December 5, 2001
Date of Patent:
July 29, 2003
Assignee:
Marine Polymer Technologies
Inventors:
John N. Vournakis, Sergio Finkielsztein, Ernest R. Pariser, Mike Helton
Abstract: A nucleic acid coating composition including a polyanion bound, directly or through one or more intermediates, to a medical device surface, with a condensate comprising a polycation and nucleic acid bound to the polyanion, devices incorporating such coating compositions, and methods for making. In one embodiment, a silyl-heparin complex is provided, bound to a medical device surface by hydrophobic interaction with the silyl moiety, with a polycation and nucleic acid condensate bound to the heparin by electrostatic interaction.
Type:
Grant
Filed:
January 22, 2002
Date of Patent:
July 22, 2003
Assignee:
BioSurface Engineering Technologies, Inc.
Inventors:
Paul O. Zamora, Ray Tsang, Shigemasa Osaki
Abstract: The present invention provides methods of inhibiting L-selectin and P-selectin mediated binding in a subject by administering heparin to the subject in an amount that does not produce substantial anticoagulant activity or undesirable bleeding in the subject. In addition, the invention provides methods of treating a subject having a pathology characterized, at least in part, by abnormal L-selectin or P-selectin mediated binding by administering heparin to the subject in an amount that results in attaining a concentration of less than about 0.2-0.4 units heparin per ml of plasma in the subject.
Type:
Grant
Filed:
February 8, 1999
Date of Patent:
July 22, 2003
Assignee:
The Regents of the University of California
Abstract: A class of proteoglycans containing fucosylated acidic glycans, e.g., as produced by marine sponges and sea urchin embryos, have been found to stimulate selective proliferation of mammalian natural killer (NK) cells and &ggr;&dgr;T cells. These compounds are useful as pharmaceuticals, particularly as immunostimulants, e.g., in the treatment of cancer and viral infections.
Abstract: Formulations for enhanced mucosal absorption of heparin are disclosed. In one embodiment, a powdered heparin composition is made by dissolving an amphiphilic heparin derivative including heparin covalently bonded to a hydrophobic agent in a water phase, dispersing the water phase in an organic phase such that an emulsion is formed, and drying the emulsion. In another embodiment, an amorphiphilic heparin derivative dispersed in an oil phase is made by dissolving the amphiphilic heparin derivative in water or a water/organic co-solvent, dispersing the water or co-solvent in the oil phase, and evaporating the water or co-solvent. In another embodiment, heparin-containing nanoparticles having surfactant molecules associated with a hydrophobic agent on the outside of the nanoparticles are made by dissolving the amphiphilic heparin derivative in an aqueous solvent, mixing the surfactant with the aqueous solvent, and disrupting nanoparticles of the amphiphilic heparin derivative.
Abstract: The present invention is directed to novel sulphated compounds of hyaluronic acid and derivatives thereof, optionally salified, wherein the glucosamines are partially N-sulphated or partially N-sulphated and partially or totally O-sulphated in position 6. The compounds of the invention have anticoagulant and antithrombotic activities and are useful in the preparation of pharmaceutical compositions and biomaterials and in the production of coatings for biomedical objects.
Abstract: A process for preparing potassium monoethyl malonate by selective saponification of malonic acid diethyl ester with potassium hydroxide, in which the potassium hydroxide is added to the malonic acid diethyl ester, malonic acid diethyl ester and potassium hydroxide are used in a molar ratio of at least 1.5 and the potassium hydroxide is effectively distributed into the malonic acid diethyl ester.